Literature DB >> 23670839

[Radiation therapy of meningioma of the anterior visual pathway].

F Paulsen1, D Zips.   

Abstract

Radiotherapy is an established alternative to surgery in the treatment of meningiomas. Particularly in cases of symptomatic tumors of the optical pathways, irradiation is the treatment of choice when the functional risks of surgery are high. Because histological findings are often lacking an interdisciplinary discussion is important to determine neuroradiological and neuro-ophthalmological patterns of the tumor. As a general benefit for immediate irradiation after subtotal resection could not yet be shown and the risk for side effects is increased, a postoperative radiotherapy has to be discussed in each individual patient. The choice of the special irradiation schedule depends on tumor size and its localization in the proximity of critical structures. Three-dimensional treatment planning with magnetic resonance imaging (MRI) information on the tumor and its surroundings is mandatory. A precise immobilization of the patient is necessary for treatment in the area of the anterior visual pathways.

Entities:  

Mesh:

Year:  2013        PMID: 23670839     DOI: 10.1007/s00347-012-2777-7

Source DB:  PubMed          Journal:  Ophthalmologe        ISSN: 0941-293X            Impact factor:   1.059


  8 in total

1.  Fractionated stereotactic radiotherapy in patients with optic nerve sheath meningioma.

Authors:  Frank Paulsen; Stefan Doerr; Helmut Wilhelm; Gerd Becker; Michael Bamberg; Johannes Classen
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-02-06       Impact factor: 7.038

2.  High symptom improvement and local tumor control using stereotactic radiotherapy when given early after diagnosis of meningioma. A multicentre study.

Authors:  I Compter; K Zaugg; R M A Houben; J T A Dings; G Bosmans; C Buescher; M M H M E Anten; B G Baumert
Journal:  Strahlenther Onkol       Date:  2012-09-09       Impact factor: 3.621

3.  High efficacy of fractionated stereotactic radiotherapy of large base-of-skull meningiomas: long-term results.

Authors:  J Debus; M Wuendrich; A Pirzkall; A Hoess; W Schlegel; I Zuna; R Engenhart-Cabillic; M Wannenmacher
Journal:  J Clin Oncol       Date:  2001-08-01       Impact factor: 44.544

4.  Fractionated stereotactic radiotherapy in patients with benign or atypical intracranial meningioma: long-term experience and prognostic factors.

Authors:  Stefanie Milker-Zabel; Angelika Zabel; Daniela Schulz-Ertner; Wolfgang Schlegel; Michael Wannenmacher; Jürgen Debus
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-03-01       Impact factor: 7.038

5.  Patterns of failure after stereotactic radiotherapy of intracranial meningioma.

Authors:  Vasileios Askoxylakis; Angelika Zabel-du Bois; Wolfgang Schlegel; Jürgen Debus; Peter Huber; Stefanie Milker-Zabel
Journal:  J Neurooncol       Date:  2009-12-13       Impact factor: 4.130

6.  Does adjuvant external-beam radiotherapy improve outcomes for nonbenign meningiomas? A Surveillance, Epidemiology, and End Results (SEER)-based analysis.

Authors:  Alexander M Stessin; Allie Schwartz; Grigorij Judanin; Susan C Pannullo; John A Boockvar; Theodore H Schwartz; Philip E Stieg; A Gabriella Wernicke
Journal:  J Neurosurg       Date:  2012-08-17       Impact factor: 5.115

Review 7.  Radiotherapy and radiosurgery for benign skull base meningiomas.

Authors:  Giuseppe Minniti; Maurizio Amichetti; Riccardo Maurizi Enrici
Journal:  Radiat Oncol       Date:  2009-10-14       Impact factor: 3.481

8.  [68Ga]-DOTATOC-PET/CT for meningioma IMRT treatment planning.

Authors:  Barbara Gehler; Frank Paulsen; Mehmet O Oksüz; Till-Karsten Hauser; Susanne M Eschmann; Roland Bares; Christina Pfannenberg; Michael Bamberg; Peter Bartenstein; Claus Belka; Ute Ganswindt
Journal:  Radiat Oncol       Date:  2009-11-18       Impact factor: 3.481

  8 in total
  2 in total

1.  Integrin-based meningioma cell migration is promoted by photon but not by carbon-ion irradiation.

Authors:  Florian Simon; Jan-Oliver Dittmar; Stephan Brons; Lena Orschiedt; Steffi Urbschat; Klaus-Josef Weber; Jürgen Debus; Stephanie E Combs; Stefan Rieken
Journal:  Strahlenther Onkol       Date:  2014-12-02       Impact factor: 3.621

2.  [Visual impairment due to rare optic nerve tumor].

Authors:  J Lenk; E Matthé; D Sandner
Journal:  Ophthalmologe       Date:  2016-04       Impact factor: 1.059

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.